Bristol-Myers Squibb Company (NYSE:BMY) is one of the best large cap value stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) without assigning a price target.
Bristol-Myers Squibb Company reported $12.3 billion in revenues in fiscal Q2 2025, with growth portfolio revenues of $6.6 billion, up 18%.
GAAP EPS for the quarter was $0.64, and non-GAAP EPS was $1.46.
Bristol-Myers Squibb Company also raised its 2025 revenue guidance to the range of ~$46.5 billion to $47.5 billion, and updated its non-GAAP EPS range to $6.35 to $6.65.
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
